Opening Project of Key Laboratory of Drug Targeting and Drug Delivery System,
Ministry of Education (Sichuan University).
7. References
Abdayem, P., Ghosn, M., Valero, V., Walters, R., Arun, B., Murray, J.L., 2014. Phase I and II study
of gemcitabine and vinorelbine in heavily pretreated patients with metastatic breast cancer
and review of the literature. J. Cancer 5(5), 351-359.
Aertgeerts, K., Levin, I., Shi, L., Snell, G.P., Jennings, A., Prasad, G.S., 2005. Structural and
kinetic analysis of the substrate specifcity of human fbroblast activation protein alpha. J. Biol.
Chem. 280, 19441-19444.
Collins, P.J., McMahon, G., O'Brienm P., 2004. Purifcation, identifcation and characterisation of
seprase from bovine serum. Int. J. Biochem. Cell Biol. 36, 2320-2333.
Dasari, M., Acharya, A.P., Kim, D., Lee, S., Rhea, J., 2013. H-gemcitabine: a new gemcitabine
prodrug for treating cancer. Bioconjug. Chem. 24(1), 4-8.
Dreiocker, F., Muller, M.Q., Sinz, A., Schafer, M., 2010. Collision-induced dissociative chemical
cross-linking reagent for protein structure characterization: applied Edman chemistry in the
gas phase. J. Mass Spectrom. 45(2), 178-189.
Dubey, R.D., Saneja, A., Gupta, P.K., Gupta, P.N., 2016. Recent advances in drug delivery
strategies for improved therapeutic efficacy of gemcitabine. Eur. J. Pharm. Sci. 93, 147-162.
Duyverman, A.M., Steller, E.J., Fukumura, D., Jain, R.K., Duda, D.G., 2012. Studying primary
tumor-associated fibroblast involvement in cancer metastasis in mice. Nat. Protoc. 7(4),
756-762.
Fan, M., Liang, X., Li, Z., Wang, H., Yang, D., Shi, B., 2015. Chlorambucil gemcitabine conjugate
nanomedicine for cancer therapy. Eur. J. Pharm. Sci. 79, 20-26.
Gesto, D.S., Cerqueira, N.M., Fernandes, P.A., Ramos, M.J., 2012. Gemcitabine: a critical
nucleoside for cancer therapy. Curr. Med. Chem. 19(7), 1076-1087.
Hoang, N.T., Kadonosono, T., Kuchimaru, T., Kizaka-Kondoh, S., 2016. Hypoxia-inducible
factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic
cancer survival in an orthotopic model. Cancer Sci. 107(8), 1151-1158.
Hou, M., Xue, P., Gao, Y.E., Ma, X., Bai, S., Kang, Y., 2017. Gemcitabine-camptothecin
conjugates: a hybrid prodrug for controlled drug release and synergistic therapeutics.
Biomater Sci. 5(9), 1889-1897.
Huang, S., Fang, R., Xu, J., Qiu, S., Zhang, H., Du, J., 2011. Evaluation of the tumor targeting of a
FAP alpha-based doxorubicin prodrug. J. Drug Target. 19(7), 487-496.
Hui, L., Chen, Y., 2015. Tumor microenvironment: Sanctuary of the devil. Cancer Lett. 368(1),
7-13.
Karampelas, T., Skavatsou, E., Argyros, O., Fokas, D., Tamvakopoulos, C., 2017. Gemcitabine
based peptide conjugate with improved metabolic properties and dual mode of efficacy. Mol.
Pharm. 14(3), 674-685.
Lai, D., Ma, L., Wang, F., 2012. Fibroblast activation protein regulates tumor-associated
fibroblasts and epithelial ovarian cancer cells. Int. J. Oncol. 41(2), 541-550.
Lee, S., Lee, Y., Kim, W., Nam, J., Jeong, S., Yoo, J.W., 2015. Evaluation of glycine-bearing
19